Lisinopril And Hydrochlorothiazide Tablet
FDA Recall NDC 68180-518
Latest: Class II · Status: Completed · Initiated Jun 20, 2025 · 5 enforcement reports
Active & Historical Enforcement Reports
The FDA has identified 5 recorded enforcement report(s) associated with Lisinopril And Hydrochlorothiazide (NDC 68180-518). A significant event, classified as Class II, was initiated on Jun 20, 2025 by Lupin Pharmaceuticals, Inc.. The reported reason for this action was: "Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg."
This specific recall has a current status of COMPLETED, indicating that the FDA considers the recall process finished or the product successfully recovered.
This specific recall has a current status of COMPLETED, indicating that the FDA considers the recall process finished or the product successfully recovered.
Reported Recall Events
Class II Completed
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Jun 20, 2025
Jul 23, 2025
58,968 bottles
Recall Profile & Regulatory Data
Event ID
97118
Classification
Class II
Enforcement Status
Completed
Recalling Firm
Lupin Pharmaceuticals Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Product was distributed nationwide within the United States.
Product Description
Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, Rx only, Mfg for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202, Manufactured by: Lupin Limited Nagpur-441 108, INDIA, NDC 68180-519-01
Batch or Lot Expiration Information
Lot# : QA01081, Exp. Date April 2027
Affected Packages Involved in this Recall
68180-518-02Lisinopril And Hydrochlorothiazide
68180-518-01Lisinopril And Hydrochlorothiazide
68180-518-30Lisinopril And Hydrochlorothiazide
68180-519-30Lisinopril And Hydrochlorothiazide
68180-519-01Lisinopril And Hydrochlorothiazide
68180-519-02Lisinopril And Hydrochlorothiazide
68180-520-02Lisinopril And Hydrochlorothiazide
68180-520-30Lisinopril And Hydrochlorothiazide
68180-520-01Lisinopril And Hydrochlorothiazide
Class II Terminated
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Jan 26, 2022
Jan 03, 2024
2 units
Recall Profile & Regulatory Data
Event ID
89450
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
CARDINAL HEALTHCARE
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide USA
Termination Date
Sep 29, 2024
Product Description
Lisinopril and Hydrochlorothiazide Tablets USP, 10mg/12.5mg, Rx only, 100 Tablets per bottles, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Nagpur-441 108, India. NDC: 68180-518-01
Batch or Lot Expiration Information
Batch# Batch Q101699, Q101981
Affected Packages Involved in this Recall
68180-518-02Lisinopril And Hydrochlorothiazide
68180-518-01Lisinopril And Hydrochlorothiazide
68180-518-30Lisinopril And Hydrochlorothiazide
68180-519-30Lisinopril And Hydrochlorothiazide
68180-519-01Lisinopril And Hydrochlorothiazide
68180-519-02Lisinopril And Hydrochlorothiazide
68180-520-02Lisinopril And Hydrochlorothiazide
68180-520-30Lisinopril And Hydrochlorothiazide
68180-520-01Lisinopril And Hydrochlorothiazide
Class II Terminated
Presence of Foreign Tablets/Capsules: Product complaint received of one Fenofibrate tablet 145mg observed in 500 s count product bottle.
Jul 19, 2019
Jul 31, 2019
11,832 bottles
Recall Profile & Regulatory Data
Event ID
83363
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Lupin Pharmaceuticals Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide within the United States
Termination Date
Sep 09, 2020
Product Description
Lisinopril and Hydrochlorothiazide Tablets USP, 20 mg/12.5 mg, 500-count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775, INDIA, NDC 68180-519-02
Batch or Lot Expiration Information
Lot# :H801815, Exp. March 2021
Affected Packages Involved in this Recall
68180-518-02Lisinopril And Hydrochlorothiazide
68180-518-01Lisinopril And Hydrochlorothiazide
68180-518-30Lisinopril And Hydrochlorothiazide
68180-519-30Lisinopril And Hydrochlorothiazide
68180-519-01Lisinopril And Hydrochlorothiazide
68180-519-02Lisinopril And Hydrochlorothiazide
68180-520-02Lisinopril And Hydrochlorothiazide
68180-520-30Lisinopril And Hydrochlorothiazide
68180-520-01Lisinopril And Hydrochlorothiazide
July 2019 Class II Recall: Presence of Foreign Substance; Product complaints received related to brownish/blackish stains on the tablets and brownish/blackish powder observed inside the bottles.
Recall Number
Class II Terminated
Presence of Foreign Substance; Product complaints received related to brownish/blackish stains on the tablets and brownish/blackish powder observed inside the bottles.
Jul 17, 2019
Aug 21, 2019
39,216 bottles
Recall Profile & Regulatory Data
Event ID
83354
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Lupin Pharmaceuticals Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Product was distributed to wholesalers/distributors and supermarket and drug chains throughout the United States.
Termination Date
Sep 14, 2020
Product Description
Lisinopril and Hydrochlorothiazide Tablets USP, 10 mg/12.5 mg, 100 tablet bottle, Rx only, Manufactured by for: Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by: Lupin Limited, Pithampur, INDIA NDC 68180-518-01
Batch or Lot Expiration Information
Batch# H900575, exp. date 01/2022
Affected Packages Involved in this Recall
68180-518-02Lisinopril And Hydrochlorothiazide
68180-518-01Lisinopril And Hydrochlorothiazide
68180-518-30Lisinopril And Hydrochlorothiazide
68180-519-30Lisinopril And Hydrochlorothiazide
68180-519-01Lisinopril And Hydrochlorothiazide
68180-519-02Lisinopril And Hydrochlorothiazide
68180-520-02Lisinopril And Hydrochlorothiazide
68180-520-30Lisinopril And Hydrochlorothiazide
68180-520-01Lisinopril And Hydrochlorothiazide
Class III Terminated
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
Apr 04, 2016
Jul 06, 2016
59,520 Bottles
Recall Profile & Regulatory Data
Event ID
73848
Classification
Class III
Enforcement Status
Terminated
Recalling Firm
Lupin Pharmaceuticals Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide and Puerto Rico
Termination Date
Jun 01, 2017
Product Description
Lisinopril & Hydrochlorothiazide Tables, USP 20mg/12.5mg, packaged in a)100-count bottles and b) 5000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775 India, a) NDC 68180-519-01, b) 68180-519-30
Batch or Lot Expiration Information
Lot# : a) H303459, b) H303460, Exp 09/2016
Affected Packages Involved in this Recall
68180-518-02Lisinopril And Hydrochlorothiazide
68180-518-01Lisinopril And Hydrochlorothiazide
68180-518-30Lisinopril And Hydrochlorothiazide
68180-519-30Lisinopril And Hydrochlorothiazide
68180-519-01Lisinopril And Hydrochlorothiazide
68180-519-02Lisinopril And Hydrochlorothiazide
68180-520-02Lisinopril And Hydrochlorothiazide
68180-520-30Lisinopril And Hydrochlorothiazide
68180-520-01Lisinopril And Hydrochlorothiazide
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.